Resmed reports 11% revenue growth and 21% EPS increase in Q3 fiscal 2026, driven by strong global demand.

Resmed Inc. announced an 11% revenue increase to $1.4 billion and a 21% rise in non-GAAP earnings per share to $2.86 for Q3 fiscal 2026, reflecting strong global demand for its sleep and breathing health products. Gross margins improved by 290 basis points due to cost efficiencies, while operating cash flow reached $554 million. The company also declared a quarterly dividend of $0.60 per share and plans to expand U.S. operations with a new distribution center. Resmed remains focused on expanding care access, scaling digital health, and sustaining profitable growth.